by Damon Race | Mar 26, 2024 | In the News
ReciBioPharm, GeneVentiv to advance GENV-HEM to Phase 1/2 clinical testing by Margarida Maia, PhD | March 15, 2024 ReciBioPharm and GeneVentiv Therapeutics are teaming up to advance the development of GENV-HEM, a gene therapy for all hemophilia patients, including...
by Damon Race | Mar 13, 2024 | Press
March 13 2024 ReciBioPharm, the advanced and emerging therapies business unit of Recipharm, has announced a collaboration agreement with GeneVentiv Therapeutics, a pre-clinical gene therapy company, to advance development of an Adeno-Associated Virus (AAV)-based...
by Damon Race | Jan 30, 2024 | Press
January 30, 2024 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood disorders, today announced it will attend the BIO CEO & Investor Conference, which will be held in New York, NY from...
by Damon Race | Nov 30, 2023 | Press
November 30, 2023 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood disorders, today announced it will attend the Biotech Showcase and BIO Partnering meetings during the J.P. Morgan...
by Damon Race | Oct 2, 2023 | Press
October 2, 2023 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood disorders, today announced it will attend BIO Investor Forum, which will be held in San Francisco, CA from October 17-18,...
Recent Comments